{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:18:29Z","timestamp":1784557109608,"version":"3.55.0"},"reference-count":141,"publisher":"Bioscientifica","issue":"10","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated signaling cascades within the tumor inaugurated a new era of oncological therapy. Recently, immunotherapy with immune checkpoint inhibitors has started to revolutionize the treatment of several malignancies, most notably malignant melanoma, leading to the renaissance and the long-awaited breakthrough of immunooncology. This review provides an overview of the basis of immunotherapy from its initial concepts of anti-tumor immunity and cell-based therapy to the development of immune checkpoint inhibitors and discusses published studies and the perspectives of immunooncology for the treatment of endocrine malignancies.<\/jats:p>","DOI":"10.1530\/erc-16-0169","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T21:58:21Z","timestamp":1470175101000},"page":"R469-R484","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":17,"title":["Perspectives for immunotherapy in endocrine cancer"],"prefix":"10.1530","volume":"23","author":[{"given":"S","family":"Latteyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Tiedje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"F\u00fchrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2016090819534722000_23.10.R469.1","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-14-0354","article-title":"GEP-NETs update: biotherapy for neuroendocrine tumours","volume":"172","author":"Alonso-Gordoa","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2016090819534722000_23.10.R469.2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0134"},{"key":"2016090819534722000_23.10.R469.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2016090819534722000_23.10.R469.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00544-6"},{"key":"2016090819534722000_23.10.R469.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"2016090819534722000_23.10.R469.6","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000175468.19742.10"},{"key":"2016090819534722000_23.10.R469.7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3892\/or_00000391","article-title":"Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma","volume":"21","author":"Bachleitner-Hofmann","year":"2009","journal-title":"Oncology Reports"},{"key":"2016090819534722000_23.10.R469.8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.2.327"},{"key":"2016090819534722000_23.10.R469.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.09.006"},{"key":"2016090819534722000_23.10.R469.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0041"},{"key":"2016090819534722000_23.10.R469.11","first-page":"4059","article-title":"Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue","volume":"71","author":"Bigelow","year":"2013","journal-title":"Journal of Visualized Experiments"},{"key":"2016090819534722000_23.10.R469.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2834"},{"key":"2016090819534722000_23.10.R469.13","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000178913.41256.06"},{"key":"2016090819534722000_23.10.R469.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903435"},{"key":"2016090819534722000_23.10.R469.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2016090819534722000_23.10.R469.16","doi-asserted-by":"crossref","first-page":"17194","DOI":"10.18632\/oncotarget.7839","article-title":"Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer","volume":"7","author":"Brauner","year":"2016","journal-title":"Oncotarget"},{"key":"2016090819534722000_23.10.R469.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"2016090819534722000_23.10.R469.18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27817"},{"key":"2016090819534722000_23.10.R469.19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4075"},{"key":"2016090819534722000_23.10.R469.20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fimmu.2014.00197","article-title":"Does the immune system naturally protect against cancer?","volume":"5","author":"Corthay","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"2016090819534722000_23.10.R469.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3670"},{"key":"2016090819534722000_23.10.R469.22","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0313"},{"key":"2016090819534722000_23.10.R469.23","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0285"},{"key":"2016090819534722000_23.10.R469.24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.1993.11.4.652","article-title":"Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2","volume":"11","author":"Curti","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"2016090819534722000_23.10.R469.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0193-z"},{"key":"2016090819534722000_23.10.R469.26","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"2016090819534722000_23.10.R469.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0315-1"},{"key":"2016090819534722000_23.10.R469.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"2016090819534722000_23.10.R469.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"2016090819534722000_23.10.R469.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2016090819534722000_23.10.R469.31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"2016090819534722000_23.10.R469.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00307-1"},{"key":"2016090819534722000_23.10.R469.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2016090819534722000_23.10.R469.34","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E"},{"key":"2016090819534722000_23.10.R469.35","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0511"},{"key":"2016090819534722000_23.10.R469.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"2016090819534722000_23.10.R469.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"2016090819534722000_23.10.R469.38","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-7-12"},{"key":"2016090819534722000_23.10.R469.39","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2016090819534722000_23.10.R469.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2016090819534722000_23.10.R469.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2016090819534722000_23.10.R469.42","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053"},{"key":"2016090819534722000_23.10.R469.43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0391"},{"key":"2016090819534722000_23.10.R469.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.025"},{"key":"2016090819534722000_23.10.R469.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3128"},{"key":"2016090819534722000_23.10.R469.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.08.010"},{"key":"2016090819534722000_23.10.R469.47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12885-016-2114-7","article-title":"Follicular thyroid carcinoma but not adenoma recruits tumor-associated macrophages by releasing CCL15","volume":"16","author":"Huang","year":"2015","journal-title":"BMC Cancer"},{"key":"2016090819534722000_23.10.R469.48","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0436"},{"key":"2016090819534722000_23.10.R469.49","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO Journal"},{"key":"2016090819534722000_23.10.R469.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"2016090819534722000_23.10.R469.51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1508516112"},{"key":"2016090819534722000_23.10.R469.52","doi-asserted-by":"crossref","unstructured":"Joseph Grosso DI Qiuyan Wu Jason Simon Parul Singh Xiaoling Zhang Therese Phillips Pauline Simmons John Cogswell 2013 Programmed death-ligand 1 (PD-L1) expression in various tumor types. Society for Immunotherapy of Cancer 28th Annual Meeting Poster presentation.","DOI":"10.1186\/2051-1426-1-S1-P53"},{"key":"2016090819534722000_23.10.R469.53","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2015.06.01"},{"key":"2016090819534722000_23.10.R469.54","doi-asserted-by":"publisher","DOI":"10.7150\/jca.13711"},{"key":"2016090819534722000_23.10.R469.55","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526090"},{"key":"2016090819534722000_23.10.R469.56","doi-asserted-by":"crossref","first-page":"327fs325","DOI":"10.1126\/scitranslmed.aaf3802","article-title":"Eco-evolution of cancer resistance","volume":"8","author":"Klement","year":"2016","journal-title":"Science Translational Medicine"},{"key":"2016090819534722000_23.10.R469.57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0047"},{"key":"2016090819534722000_23.10.R469.58","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2119-2"},{"key":"2016090819534722000_23.10.R469.59","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer","volume":"1","author":"Kradin","year":"1989","journal-title":"Lancet"},{"key":"2016090819534722000_23.10.R469.60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"2016090819534722000_23.10.R469.61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9020"},{"key":"2016090819534722000_23.10.R469.62","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0178"},{"key":"2016090819534722000_23.10.R469.63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.15.8099"},{"key":"2016090819534722000_23.10.R469.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.09.031"},{"key":"2016090819534722000_23.10.R469.65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271"},{"key":"2016090819534722000_23.10.R469.66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"2016090819534722000_23.10.R469.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2016090819534722000_23.10.R469.68","doi-asserted-by":"publisher","DOI":"10.1038\/85330"},{"key":"2016090819534722000_23.10.R469.69","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fimmu.2015.00418","article-title":"Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators.","volume":"6","author":"Le Mercier","year":"2015","journal-title":"Frontiers in Immunology"},{"key":"2016090819534722000_23.10.R469.70","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"2016090819534722000_23.10.R469.71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/or.2015.4435","article-title":"Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells","volume":"35","author":"Leng","year":"2016","journal-title":"Oncology Reports"},{"key":"2016090819534722000_23.10.R469.72","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011112-140341"},{"key":"2016090819534722000_23.10.R469.73","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2014_081"},{"key":"2016090819534722000_23.10.R469.74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"2016090819534722000_23.10.R469.75","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22617"},{"key":"2016090819534722000_23.10.R469.76","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23706"},{"key":"2016090819534722000_23.10.R469.77","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw181"},{"key":"2016090819534722000_23.10.R469.78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2412"},{"key":"2016090819534722000_23.10.R469.79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003345107"},{"key":"2016090819534722000_23.10.R469.80","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euf.2015.03.004","article-title":"Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma","volume":"1","author":"McDaniela","year":"2015","journal-title":"European Urology Focus"},{"key":"2016090819534722000_23.10.R469.81","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490"},{"key":"2016090819534722000_23.10.R469.82","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3973"},{"key":"2016090819534722000_23.10.R469.83","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0833"},{"key":"2016090819534722000_23.10.R469.84","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700203"},{"key":"2016090819534722000_23.10.R469.85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2016090819534722000_23.10.R469.86","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000157940.80538.ec"},{"key":"2016090819534722000_23.10.R469.87","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds295"},{"key":"2016090819534722000_23.10.R469.88","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1"},{"key":"2016090819534722000_23.10.R469.89","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1022565"},{"key":"2016090819534722000_23.10.R469.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.05.021"},{"key":"2016090819534722000_23.10.R469.91","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2015.126"},{"key":"2016090819534722000_23.10.R469.92","first-page":"45","article-title":"Intra-lymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study","volume":"7","author":"Pizza","year":"1988","journal-title":"Lymphokine Research"},{"key":"2016090819534722000_23.10.R469.93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"2016090819534722000_23.10.R469.94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6112"},{"key":"2016090819534722000_23.10.R469.95","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"2016090819534722000_23.10.R469.96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2016090819534722000_23.10.R469.97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2016090819534722000_23.10.R469.98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2016090819534722000_23.10.R469.99","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.4049\/jimmunol.150.4.1244","article-title":"Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant","volume":"150","author":"Rock","year":"1993","journal-title":"Journal of Immunology"},{"key":"2016090819534722000_23.10.R469.100","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198910000-00008"},{"key":"2016090819534722000_23.10.R469.101","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031074"},{"key":"2016090819534722000_23.10.R469.102","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c"},{"key":"2016090819534722000_23.10.R469.103","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0499"},{"key":"2016090819534722000_23.10.R469.104","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0036"},{"key":"2016090819534722000_23.10.R469.105","doi-asserted-by":"publisher","DOI":"10.1038\/ni988"},{"key":"2016090819534722000_23.10.R469.106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"2016090819534722000_23.10.R469.107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470"},{"key":"2016090819534722000_23.10.R469.108","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.10.4965"},{"key":"2016090819534722000_23.10.R469.109","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4971"},{"key":"2016090819534722000_23.10.R469.110","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80123-5"},{"key":"2016090819534722000_23.10.R469.111","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.09.017"},{"key":"2016090819534722000_23.10.R469.112","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000007"},{"key":"2016090819534722000_23.10.R469.113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11476"},{"key":"2016090819534722000_23.10.R469.114","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006504"},{"key":"2016090819534722000_23.10.R469.115","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-515"},{"key":"2016090819534722000_23.10.R469.116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"2016090819534722000_23.10.R469.117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2016090819534722000_23.10.R469.118","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.1988.6.5.839","article-title":"Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study","volume":"6","author":"Topalian","year":"1988","journal-title":"Journal of Clinical Oncology"},{"key":"2016090819534722000_23.10.R469.119","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1393"},{"key":"2016090819534722000_23.10.R469.120","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2016090819534722000_23.10.R469.121","first-page":"609","article-title":"Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion","volume":"70","author":"Vadhan-Raj","year":"1986","journal-title":"Cancer Treatment Reports"},{"key":"2016090819534722000_23.10.R469.122","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095"},{"key":"2016090819534722000_23.10.R469.123","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(65)80334-1"},{"key":"2016090819534722000_23.10.R469.124","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"2016090819534722000_23.10.R469.125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2541"},{"key":"2016090819534722000_23.10.R469.126","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.985"},{"key":"2016090819534722000_23.10.R469.127","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2016090819534722000_23.10.R469.128","first-page":"[in press]","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","author":"Weide","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"2016090819534722000_23.10.R469.129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"2016090819534722000_23.10.R469.130","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"2016090819534722000_23.10.R469.131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2016090819534722000_23.10.R469.132","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620"},{"key":"2016090819534722000_23.10.R469.133","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5450"},{"key":"2016090819534722000_23.10.R469.134","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2006.01.003"},{"key":"2016090819534722000_23.10.R469.135","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31824d4465"},{"key":"2016090819534722000_23.10.R469.136","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-0631"},{"key":"2016090819534722000_23.10.R469.137","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156e47e"},{"key":"2016090819534722000_23.10.R469.138","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12060"},{"key":"2016090819534722000_23.10.R469.139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-310425"},{"key":"2016090819534722000_23.10.R469.140","doi-asserted-by":"publisher","DOI":"10.1038\/ni1271"},{"key":"2016090819534722000_23.10.R469.141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/23\/10\/R469.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/23\/10\/R469.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:53:42Z","timestamp":1784555622000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/23\/10\/R469-R484\/33932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":141,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1530\/erc-16-0169","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}